Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Merck Sharp & Dohme LLC
Robin Kate Kelley; Makoto Ueno; Changhoon Yoo; Richard S Finn; Junji Furuse; Zhenggang Ren; Thomas Yau; Heinz-Josef Klümpen; Stephen L Chan; Masato Ozaka; Chris Verslype; Mohamed Bouattour; Joon Oh Park; Olga Barajas; Uwe Pelzer; Juan W Valle; Li Yu; Usha Malhotra; Abby B Siegel; Julien Edeline; Arndt Vogel; KEYNOTE-966 Investigators
Biostatistics and Research Decision Sciences, Merck & Co, Rahway, NJ, USA.